Mitazalimab is under clinical development by Alligator Bioscience and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mitazalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mitazalimab overview
Mitazalimab (ADC-1013) is under development for the treatment of advanced solid tumors like non-small cell lung cancer (NSCLC), metastatic pancreatic ductal adenocarcinoma, cutaneous melanoma, prostate cancer, renal cell cancer, bladder cancer and transitional cell carcinoma (urothelial cell carcinoma). The drug candidate is administered intra-tumorally and through intravenous infusion. It acts by targeting CD40. It is a monospecific, IgG1 antibody. ADC-1013 is developed by using ALLIGATOR-13, a fully human antibody library, and FIND (Fragment INduced Diversity), an in vitro based antibody optimization technology. It is based on IMCAN concept. The drug candidate is a new molecular entity (NME).
Alligator Bioscience overview
Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. Its pipeline products include mitazalimab treats solid metastatic tumors and pancreatic cancer; ATOR-4066 targets solid metastatic tumors; ALG.APV-527 for solid metastatic tumors and ATOR-1017 targets solid metastatic tumors. Its Partner Programs include AC101/HLX22 for gastric cancer and bispecific program. It develops immunotherapeutic product candidates using proprietary technologies such as Alligator-Gold and fragment-induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.
For a complete picture of Mitazalimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
